<DOC>
	<DOC>NCT02185014</DOC>
	<brief_summary>This study will evaluate the long term efficacy, safety, and tolerability of repeated administration of adalimumab in subjects with Crohn's disease.</brief_summary>
	<brief_title>Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject successfully enrolled in and completed Study M14115, including the Week 12 ileocolonoscopy. If the Week 12 (Study M14115) colonoscopy shows evidence of dysplasia or malignancy. Subject is not in compliance with prior and concomitant medication requirements throughout M14115. Subject who developed active Tuberculosis (TB) during M14115, or subject who is non compliant with prophylaxis for latent TB initiated per M14115 procedures.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crohn's Disease</keyword>
</DOC>